AIDS Research Alliance

From Wikipedia, the free encyclopedia
Jump to: navigation, search
AIDS Research Alliance of America
AIDS Research Alliance logo.png
Founded 1989
Headquarters
Key people

Carolyn H. Carlburg, J.D., Chief Executive Officer

Stephen J. Brown, M.D., Medical Director
Area served United States
Motto From hope to cure.
Website AIDS Research Alliance: Home


AIDS Research Alliance of America (ARAA) is a national community-based 501(c)3 non-profit medical research institution that seeks to develop a cure for HIV/AIDS, medical strategies to prevent new HIV infections and better treatments for people living with HIV/AIDS.[1] Since 1989, ARAA has conducted over 150 clinical and pre-clinical studies,[2] ranging from alternative therapies[3][4][5] that employ a complementary approach to HIV care to the first in-human HIV vaccine trial.[6] AIDS Research Alliance is responsible for "fast-tracking" to market half of today's anti-HIV treatments.

History[edit]

In 1989, a group of Southern California physicians and philanthropists, led by Paul Joseph Rothman, M.D. and Matthew Rushton, Hollywood film producer of Mrs. Doubtfire, founded Search Alliance to speed the discovery and development of effective treatments against HIV and its complications.[7]

Working with physicians who were experimenting with potential treatments in their private practices, the organization pooled data and identified promising experimental regimens. The staff designed the studies, coordinated the data collection of Alliance physicians, and analyzed and published the results.[8]

In 1995, Search Alliance changed its name to AIDS Research Alliance of America and centralized all research activities in one licensed facility based in Los Angeles.[8] This allowed ARAA to identify and manage scientific, clinical and organizational strategies with a staff of dedicated research professionals, while maintaining affiliations with physicians, academics and scientists in research institutions around the world.[9][10][11][12]

In 2009, ARAA relocated from West Hollywood, where it had been located for 14 years, to a larger research facility in downtown Los Angeles.[13]

As a community-based organization, ARAA serves as a bridge between communities at risk of HIV and government funded research. It collaborates with government-sponsored researchers and pharmaceutical companies, but also advocates for and conducts research that is not driven by the demand for profitability.[14] ARAA has been licensed by the National Institutes of Health (NIH) to develop a drug to combat HIV - prostratin.[15] Carolyn H. Carlburg, J.D. is the current President and Chief Executive Officer,[16][17] and Stephen J. Brown, M.D. is the current Vice President and Medical Director.[18]

Research[edit]

Today, AIDS Research Alliance of America focuses its research and development program on several core areas, including the clinical trials of anti-HIV drugs that inhibit the virus in novel ways, and new medical strategies – like microbicides and vaccines – that prevent the spread of HIV.[19] ARAA conducts clinical trials aimed at treating the medical disorders that accompany HIV, including HIV-associated lipodystrophy,[20] diarrhea and neuropathy.[21] Developing strategies that will eliminate HIV viral reservoirs has become a major research initiative of ARAA.[22] This includes its work on prostratin,[23] a potential reservoir ablative agent that ARAA has in-licensed from NIH.[15] In 2008, ARAA filed a new patent on prostratin and its analogues, thus broadening its research platform targeting the HIV reservoirs.[24]

Funding[edit]

AIDS Research Alliance of America funds its research by using a business model that includes contract research as well as tax-deductible donations from private individuals, corporations and foundations. ARAA conducts clinical trials for major pharmaceutical sponsors including Pfizer, Merck, Theratechnologies, Schering-Plough, Tibotec, NeurogesX, National Institutes of Health, Serono, Bristol-Myers Squibb, Agouron, GlaxoSmith Kline, Orasure Technologies, Gilead Sciences, and many others.[25][26][27][28]

Funders and partners to ARAA have included The Ahmanson Foundation, Capital Group Companies, City of West Hollywood, Concord Music Group, David Michod, Douglas MacBride Kinney, Entertainment AIDS Alliance, The Joseph Drown Foundation, Kaiser Permanente, MacHeist,[29] The MacDonald Family Foundation, The Pepsi Refresh Project, The Silva Watson Moon Walk Fund, The University Wide AIDS Research Program [the University of California], the Division of AIDS [NIH], Until There is a Cure, and many others.[30]

ARAA participates each year in the Combined Federal Campaign,[31] as part of the Medical Research Charities Federation and receives high ratings from the American Institute of Philanthropy[32] and Charity Navigator.[33] ARAA hosts a number of fundraising events – including ArtSeen featuring A Taste of Los Angeles[34] and has been a beneficiary of events like Macy’s Passport In-Store, Spinning Nation and the Game Show Congress. ARAA is a permanent member of the Global Giving Foundation online fundraising platform and has a partnership with We-care.com, an online charity mall. ARAA is also a beneficiary of the Ralph's Community Contribution Program in Los Angeles.

ARAA has earned three and four-star ratings from Charity Navigator for exceeding or meeting industry standards and performing as well as or better than most charities in its space.[35]

References[edit]

  1. ^ "CenterWatch Research Center Profile Pages". Centerwatch.com. Retrieved January 12, 2012. 
  2. ^ "CenterWatch". Search.centerwatch.com. Retrieved January 12, 2012. 
  3. ^ J Kaiser, J Ondercin, G Santos, G Leoung, S Brown, M Mass, M Baum (February 8–11, 2004). "Broad-Spectrum Micronutrient Supplementation in HIV-infected Patients With Dideoxynucleoside-related Peripheral Neuropathy: A Prospective, Double-Blind, Placebo Controlled Trial". 11th Conference on Retroviruses and Opportunistic Infections. San Francisco. [dead link]
  4. ^ "Foundation for Integrative AIDS Research Report on the 11th Conference on Retroviruses and Opportunistic Infections, February 2004". Fiar.us. February 10, 2004. Retrieved January 12, 2012. 
  5. ^ Bergner, Paul (2001). "Allium sativum: Antibiotic and Immune Properties". Medical Herbalism. North American Institute of Medical Herbalism. Archived from the original on August 17, 2004. Retrieved February 23, 2013. 
  6. ^ Brown SJ; Harro C; Mayer KH; Bartholow BN; Buchbinder S; Mastro TD; Judson F; Gorse GJ et al. (July 2003). "VaxGen AIDSVAX B/B Vaccine Trial: Recruitment, Demographics, and Changes in Risk Behaviors - Lessons for Future Trials.". National HIV Prevention Conference. Atlanta, Georgia, United States. T3-D0502. Retrieved February 23, 2013. 
  7. ^ "AIDS Research Alliance website". Aidsresearch.org. Archived from the original on 2009-06-11. Retrieved January 12, 2012. 
  8. ^ a b "AIDS Research Alliance website, retrieved 05/01/09". Aidsresearch.org. Archived from the original on 2009-06-11. Retrieved January 12, 2012. 
  9. ^ Poles, Michael A.; Boscardin, W. John; Elliott, Julie; Taing, Philip; Fuerst, Marie M.P.; McGowan, Ian; Brown, Stephen; Anton, Peter A. (2006). "Lack of Decay of HIV-1 in Gut-Associated Lymphoid Tissue Reservoirs in Maximally Suppressed Individuals". Journal of Acquired Immune Deficiency Syndromes 43 (1): 65–8. doi:10.1097/01.qai.0000230524.71717.14. PMID 16936559. Lay summaryScienceDaily (August 26, 2006). 
  10. ^ "Anorectal Microbicide Project – Rectal Health Behaviors & Microbicide Acceptability. consent form; National Institutes of Health June 2006". Mdp.ctrl.ucla.edu. Retrieved January 12, 2012. 
  11. ^ Biancotto, A.; Grivel, J.-C.; Gondois-Rey, F.; Bettendroffer, L.; Vigne, R.; Brown, S.; Margolis, L. B.; Hirsch, I. (2004). "Dual Role of Prostratin in Inhibition of Infection and Reactivation of Human Immunodeficiency Virus from Latency in Primary Blood Lymphocytes and Lymphoid Tissue". Journal of Virology 78 (19): 10507–15. doi:10.1128/JVI.78.19.10507-10515.2004. PMC 516376. PMID 15367617. 
  12. ^ Hendrix, CW; Collier, AC; Lederman, MM; Schols, D; Pollard, RB; Brown, S; Jackson, JB; Coombs, RW; Glesby, MJ; Flexner, CW; Bridger, GJ; Badel, K; MacFarland, RT; Henson, GW; Calandra, G; Amd3100 Hiv Study, Group (2004). "Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection". Journal of acquired immune deficiency syndromes 37 (2): 1253–62. PMID 15385732. 
  13. ^ Research space: AIDS Research Alliance has leased office space at the California Professional Center building. Los Angeles Business Journal 12/01/08
  14. ^ Trials By Fire. Williams, S; POZ No. 12, P. 56; (02/96-03/96)
  15. ^ a b "Federal Register 2000: 65 FR 79873 Prospective Grant of Exclusive License: Treatment of HIV". Loislaw.com. Retrieved January 12, 2012. 
  16. ^ "Forbes.com retrieved 05/08/06". Forbes. Retrieved January 12, 2012. 
  17. ^ "The Chronicle of Philanthropy v.17 06/01/2005". Philanthropy.com. May 12, 2005. Retrieved January 12, 2012. 
  18. ^ "AIDS Researchers Say the Work is Personal. Fair F; NYU Journalism School – NYC Pavement Pieces 01/11/08". Journalism.nyu.edu. Retrieved January 12, 2012. 
  19. ^ "AIDS Research Alliance website". Aidsresearch.org. Retrieved January 12, 2012. [dead link]
  20. ^ Grunfeld, C; Leighty, M; Shen, SJ; Brouwers, G; Lee, D; Muurahainen, N; Kotler, DP; Study 24380 Investigators, Group (2007). "Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy". Journal of acquired immune deficiency syndromes (1999) 45 (3): 286–97. doi:10.1097/QAI.0b013e3180691145. PMID 17592343. INIST:18907012. 
  21. ^ Simpson, D. M.; Brown, S.; Tobias, J.; Ngx-4010 c107 Study, Group (2008). "Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy". Neurology 70 (24): 2305–13. doi:10.1212/01.wnl.0000314647.35825.9c. PMID 18541884. 
  22. ^ Stix, Gary (May 13, 2008). "Luring HIV from Hiding". Scientific American. Retrieved January 12, 2012. 
  23. ^ Hezareh, M (2005). "Prostratin as a new therapeutic agent targeting HIV viral reservoirs". Drug news & perspectives 18 (8): 496–500. doi:10.1358/dnp.2005.18.8.944543. PMID 16391719. 
  24. ^ Methods of Administering Prostratin and Structured Analogues Thereof. United States Patent and Trademark Office (USPTO) (ISA/US), April 11, 2008
  25. ^ "Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles". AIDS Treatment News (332): 8. 1999. PMID 11367131. 
  26. ^ "Business Wire 03/29/01". Aegis.com. March 29, 2001. Retrieved January 12, 2012. 
  27. ^ PR Newswire September 17, 1995[dead link]
  28. ^ "Financial Times – Europe Intelligence Wire 08/29/06". Accessmylibrary.com. August 29, 2006. Retrieved January 12, 2012. 
  29. ^ MacHeist raises $500,000 for Charity. Wolsey, G; MacTeens Magazine December 14, 2006
  30. ^ "AIDS Research Alliance 2007 Annual Report". Aidsresearch.org. Retrieved January 12, 2012. [dead link]
  31. ^ "Federal Globe website". Fedglobe.org. Retrieved January 12, 2012. 
  32. ^ Daniel Borochoff (August 24, 2002). "American Institute of Philanthropy Charity Listing". Charitywatch.org. Retrieved January 12, 2012. 
  33. ^ "Charity Navigator". Charity Navigator. Retrieved January 12, 2012. 
  34. ^ "YouTube ArtSeen Footage". Youtube. June 4, 2007. Retrieved January 12, 2012. 
  35. ^ "Charity Navigator". Charity Navigator. Charity Navigator. Retrieved 5 April 2012. 

External links[edit]